

France Next-Generation Sequencing Market By Product (Consumables, Platforms, Services), By Consumables (Sample preparation consumables, Other Consumables), By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms), By Services (Sequencing Services, Data management services), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others), By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others), By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others), By Region, By Competition Forecast & Opportunities, 2018-2028F

Market Report | 2023-11-07 | 87 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

Report description:

France Next-Generation Sequencing Market is anticipated to project impressive growth in the forecast period. The France

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Next-Generation Sequencing (NGS) market is experiencing significant growth and innovation, driven by advancements in genomic research, personalized medicine, and increasing applications across various fields. Key players in the market are actively contributing to technological developments, resulting in improved sequencing accuracy, reduced costs, and enhanced data analysis capabilities.

Key Market Drivers

Research and Development Initiatives

Research and Development (R&D) initiatives have emerged as powerful drivers of innovation and progress, particularly in the field of genomics. In the vibrant scientific landscape of France, these initiatives play a pivotal role in shaping the trajectory of the Next-Generation Sequencing (NGS) market. As the nation continues to invest in cutting-edge genomics research, the synergistic relationship between R&D efforts and the NGS market is unlocking new possibilities and fueling unprecedented growth.

R&D initiatives are the engine that propels technological advancements in NGS platforms. Continuous investment in R&D allows for the exploration and development of novel sequencing technologies, improving the efficiency, accuracy, and cost-effectiveness of NGS. By pushing the technological frontiers, researchers can expand the capabilities of NGS, making it a more versatile and powerful tool for genomic analysis.

R&D initiatives contribute to the discovery and development of innovative applications for NGS technologies. As researchers delve deeper into the intricacies of genomics, new possibilities for using NGS emerge. This includes applications in fields such as personalized medicine, rare disease diagnosis, and agricultural genomics. R&D-driven innovations open up avenues for diverse industries to harness the potential of NGS, driving market growth through increased adoption.

R&D initiatives often foster collaboration between academic institutions, research organizations, and industry players. These collaborative efforts create a dynamic ecosystem where knowledge exchange and shared resources accelerate the development and application of NGS technologies. The synergy between researchers and industry experts contributes to a more comprehensive understanding of genomic data and facilitates the translation of discoveries into market-ready solutions.

Investment in R&D initiatives attracts top talent and expertise to the genomics sector. Researchers, scientists, and skilled professionals are drawn to environments that prioritize innovation and exploration. The infusion of diverse perspectives and expertise enhances the collective capabilities of the genomics community, driving breakthroughs in NGS technologies and applications.

Advancements in Technology

In the dynamic landscape of genomics, technological advancements are the driving force propelling the Next-Generation Sequencing (NGS) market to new heights. In France, a hotbed of scientific innovation, the intersection of cutting-edge technologies and genomics research is reshaping the future of healthcare, diagnostics, and biotechnology.

Advancements in NGS technologies are synonymous with enhanced precision and accelerated sequencing speeds. Modern NGS platforms leverage innovations such as improved chemistry, sequencing-by-synthesis techniques, and optimized bioinformatics algorithms. This not only ensures more accurate and reliable results but also significantly reduces the time required for genomic analysis. As the technology becomes more efficient, it becomes more accessible, contributing to increased adoption and market expansion.

Continuous technological advancements in NGS have led to a significant reduction in the overall cost of sequencing. As the cost per base pair decreases, NGS becomes more economically viable for research institutions, clinics, and biotechnology companies. This cost-effectiveness drives broader adoption and opens up new avenues for smaller research labs and healthcare providers to leverage NGS technologies, contributing to market growth.

Innovations in NGS technologies are expanding the range of applications across various domains. From genomics and transcriptomics to epigenomics and metagenomics, advanced NGS platforms offer versatile solutions for researchers and clinicians. The ability to capture a more comprehensive view of the genome allows for diverse applications, including disease research, drug discovery, and agricultural genomics. This versatility is a key driver in the market's growth, as NGS becomes an indispensable tool across multiple industries.

One notable technological leap is the emergence of single-cell sequencing technologies. Traditional sequencing methods often provide averaged results from a population of cells, masking individual variations. Single-cell sequencing enables researchers to analyze the genomic information of individual cells, offering unprecedented insights into cellular heterogeneity. This innovation is

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

particularly valuable in understanding complex biological systems, unraveling the intricacies of diseases, and advancing personalized medicine.

Clinical Applications and Precision Medicine

In the realm of genomics, the convergence of Next-Generation Sequencing (NGS) technologies with clinical applications and precision medicine is heralding a new era in healthcare. In France, a nation renowned for its commitment to scientific progress, the marriage of genomics and personalized medicine is emerging as a powerful driver of growth for the NGS market.

Clinical applications of NGS are transforming the landscape of diagnostics, offering a paradigm shift from traditional methods. The ability to sequence entire genomes or specific gene regions provides clinicians with a comprehensive and detailed understanding of genetic variations associated with diseases. NGS enables precise and early diagnosis, particularly in cases of rare genetic disorders, oncology, and infectious diseases, revolutionizing patient care and treatment strategies.

Precision medicine, an approach that tailors medical treatment to the individual characteristics of each patient, relies heavily on genomic information. NGS technologies play a pivotal role in identifying genetic mutations, biomarkers, and therapeutic targets that inform personalized treatment strategies. The integration of genomics into clinical decision-making ensures that patients receive treatments that are not only more effective but also less prone to adverse reactions.

NGS has emerged as a cornerstone in oncology research and treatment. The comprehensive genomic profiling enabled by NGS allows oncologists to identify specific genetic alterations driving cancer development. This information is invaluable in selecting targeted therapies and predicting treatment response, leading to more effective cancer management. As precision oncology gains momentum, the demand for NGS in oncological applications is a significant driver of market growth.

Precision medicine is particularly impactful in the realm of rare diseases, where traditional diagnostic methods often fall short. NGS facilitates the identification of rare genetic variants responsible for these conditions, enabling quicker and more accurate diagnoses. The information gleaned from genomic sequencing aids in understanding the underlying mechanisms of rare diseases and informs the development of targeted therapies, providing hope for patients and driving the adoption of NGS in clinical settings.

Rising Prevalence of Genetic Disorders and Oncology Research

In the ever-evolving landscape of genomics, the rising prevalence of genetic disorders and the fervent exploration of oncology research are emerging as powerful catalysts propelling the growth of France's Next-Generation Sequencing (NGS) market. As the scientific community and healthcare providers in France increasingly recognize the potential of NGS in unraveling the complexities of genetic disorders and advancing precision oncology, the market is witnessing a surge in demand.

The prevalence of genetic disorders is on the rise, presenting a formidable challenge for healthcare systems worldwide. These disorders, often characterized by mutations in the DNA sequence, demand a nuanced and comprehensive approach for accurate diagnosis and effective management. NGS technologies, with their ability to sequence the entire genome or targeted gene regions, provide a powerful tool for identifying genetic variations associated with diverse disorders. The comprehensive genetic information offered by NGS is invaluable in unraveling the intricate genetic landscapes of conditions ranging from rare genetic diseases to more common hereditary disorders.

NGS is at the forefront of enabling precision medicine in the realm of genetic disorders. The detailed genomic insights provided by NGS facilitate personalized treatment strategies tailored to an individual's genetic makeup. As the field of pharmacogenomics expands, NGS technologies contribute to understanding how genetic variations influence responses to medications, paving the way for more targeted and effective therapeutic interventions. This intersection of genomics and precision medicine is propelling the adoption of NGS in clinical settings, driving market growth.

Oncology research is undergoing a profound transformation with the integration of genomics and NGS technologies. As cancer is fundamentally a genetic disease driven by mutations, NGS provides a revolutionary tool for deciphering the genomic alterations that underlie cancer development and progression. Through comprehensive genomic profiling, NGS enables oncologists to identify specific mutations, characterize tumor heterogeneity, and guide the selection of targeted therapies. The increasing emphasis on precision oncology is propelling the demand for NGS in cancer research and clinical applications.

Key Market Challenges

Data Management and Analysis

One of the primary challenges in the NGS landscape is the overwhelming volume of data generated with each sequencing run.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The massive datasets produced by NGS platforms require sophisticated computational infrastructure and robust bioinformatics tools for efficient storage, processing, and analysis. As the scale and complexity of genomic data increase, researchers and healthcare professionals face the ongoing challenge of managing and extracting meaningful insights from this wealth of information.

Standardization and Quality Control

The lack of standardized protocols across different NGS platforms and workflows poses a challenge in ensuring consistency and comparability of results. Standardization is crucial for facilitating data exchange, collaboration, and reproducibility of research findings. Quality control measures must be rigorously implemented to address variations in sequencing output, reducing the risk of errors and ensuring the reliability of genomic data across different laboratories and institutions.

Cost and Accessibility

While the cost of NGS has significantly decreased over the years, it remains a substantial investment for many research institutions, clinics, and smaller laboratories. The initial capital expenditure, coupled with ongoing maintenance and operational costs, can be a barrier to adoption, particularly for smaller entities with limited budgets. Addressing cost concerns and enhancing accessibility to NGS technologies are crucial factors in ensuring widespread adoption across diverse research and healthcare settings.

Key Market Trends

Integration of Multi-Omics Approaches

As researchers seek a more comprehensive understanding of biological systems, the integration of multi-omics approaches is emerging as a key trend. Combining genomics with other -omics disciplines such as transcriptomics, proteomics, and metabolomics allows for a holistic view of biological processes. This trend is anticipated to drive the development of integrated NGS platforms capable of generating diverse -omics data, enabling researchers to unravel complex biological interactions and pathways.

Advancements in Single-Cell Sequencing

Single-cell sequencing is gaining prominence as a powerful tool to explore cellular heterogeneity and understand individual cell behaviors. The technology's ability to analyze the genomic information of individual cells provides unprecedented insights into complex biological systems. Anticipated advancements in single-cell sequencing methodologies and technologies will likely broaden its applications, ranging from developmental biology to cancer research, offering a finer resolution in genomics studies.

Long-Read Sequencing Technologies

Long-read sequencing technologies are set to play a pivotal role in overcoming the limitations of short-read sequencing. The ability to sequence longer DNA fragments facilitates more accurate genome assembly, particularly in regions with repetitive sequences. This trend is expected to enhance the resolution of genomic studies, allowing researchers to explore complex genomic structures, identify structural variations, and delve deeper into the intricacies of the human genome.

Segmental Insights

Technology Insights

Based on Technology, Sequencing by Synthesis (SBS) is poised to dominate the Next-Generation Sequencing (NGS) market in France due to its unparalleled advantages and technological advancements. With its ability to simultaneously sequence millions of DNA strands, SBS offers high throughput and cost-effectiveness, making it an attractive choice for genomic research and clinical applications. The precision and accuracy of SBS technology contribute to its widespread adoption in diverse fields such as personalized medicine, agriculture, and environmental studies. Additionally, ongoing research and development efforts continue to enhance the efficiency and scalability of SBS, ensuring its sustained relevance in the rapidly evolving genomics landscape. As the demand for comprehensive and precise genomic data intensifies, Sequencing by Synthesis is well-positioned to emerge as the dominant technology in the French NGS market, driving innovation and transformative breakthroughs in various scientific disciplines.

Application Insights

Based on Application, Biomarkers and cancer-related applications are poised to dominate the Next-Generation Sequencing (NGS) market in France due to the critical role they play in advancing personalized medicine and improving patient outcomes. The increasing focus on precision medicine has heightened the demand for NGS technologies capable of identifying and analyzing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

biomarkers associated with various cancers. NGS facilitates the comprehensive profiling of genomic alterations, enabling healthcare professionals to tailor treatment plans based on the unique genetic makeup of individual patients. This approach not only enhances the efficacy of cancer therapies but also contributes to early detection and monitoring of the disease. The continuous advancements in NGS technologies, coupled with a growing emphasis on cancer research and diagnostics, position biomarkers and cancer-related applications as central drivers in the French NGS market. The ability of NGS to unravel the complexities of cancer genetics underscores its pivotal role in shaping the future of oncology in the region.

Regional Insights

Northern France is poised to dominate the Next-Generation Sequencing (NGS) market in the country due to a confluence of strategic factors. The region boasts a robust infrastructure for research and development, housing renowned academic institutions, cutting-edge biotechnology companies, and well-established healthcare facilities. This collaborative ecosystem fosters innovation and accelerates the adoption of advanced genomics technologies, including NGS. Additionally, Northern France's strategic geographical location positions it as a key hub for logistics and distribution, facilitating the seamless integration of NGS technologies into clinical settings. The region's proactive approach to fostering a favorable business environment, coupled with government initiatives supporting genomics research, further propels Northern France as a leader in the NGS market. The convergence of these factors underscores Northern France's potential to not only drive technological advancements but also to attract investments and collaborations, making it a dominant force in shaping the landscape of Next-Generation Sequencing in the country.

Key Market Players

Illumina France

Roche Diagnostics France SAS

Agilent Technologies, Inc.

Perkinelmer Inc.

Amgen Inc.

Takara Bio Europe

Report Scope:

In this report, the France Next-Generation Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□ France Next-Generation Sequencing Market, By Product:

o□ Consumables

o□ Platforms

o□ Services

□□ France Next-Generation Sequencing Market, By Technology:

o□ Sequencing by Synthesis

o□ Ion Semiconductor Sequencing

o□ Sequencing by Ligation

o□ Single Molecule Real Time Sequencing

o□ Others

□□ France Next-Generation Sequencing Market, By End User:

o□ Academic & Clinical Research Centers

o□ Pharmaceutical & Biotechnology Companies

o□ Hospitals & Clinics

o□ Others

□□ France Next-Generation Sequencing Market, By Application:

o□ Biomarkers & Cancer

o□ Diagnostics

o□ Reproductive Health

o□ Personalized Medicine

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

o Agriculture & Animal Research

o Others

□ France Next-Generation Sequencing Market, By Region:

o Northern France

o Southern France

o Western France

o Central France

o Eastern France

o Southwestern France

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the France Next-Generation Sequencing Market.

Available Customizations:

France Next-Generation Sequencing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. France Next-Generation Sequencing Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Product (Consumables, Platforms, Services)

5.2.1.1. By Consumables (Sample preparation consumables, Other Consumables)

5.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)

5.2.1.3. By Services (Sequencing Services, Data management services)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.2.□By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
- 5.2.3.□By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
- 5.2.4.□By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 5.2.5.□By Region
- 5.2.6.□By Company (2022)
- 5.3.□Market Map
- 5.3.1. By Product
- 5.3.2. By Technology
- 5.3.3. By End User
- 5.3.4. By Application
- 5.3.5. By Region
- 6.□Northern France Next-Generation Sequencing Market Outlook
- 6.1.□Market Size & Forecast□
- 6.1.1.□By Value
- 6.2.□Market Share & Forecast
- 6.2.1.□By Product (Consumables, Platforms, Services)
- 6.2.1.1.□By Consumables (Sample preparation consumables, Other Consumables)
- 6.2.1.2.□By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)
- 6.2.1.3.□By Services (Sequencing Services, Data management services)
- 6.2.2.□By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
- 6.2.3.□By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
- 6.2.4.□By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 7.□Southern France Next-Generation Sequencing Market Outlook
- 7.1.□Market Size & Forecast□
- 7.1.1.□By Value
- 7.2.□Market Share & Forecast
- 7.2.1.□By Product (Consumables, Platforms, Services)
- 7.2.1.1.□By Consumables (Sample preparation consumables, Other Consumables)
- 7.2.1.2.□By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)
- 7.2.1.3.□By Services (Sequencing Services, Data management services)
- 7.2.2.□By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
- 7.2.3.□By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
- 7.2.4.□By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 8.□Western France Valencia Next-Generation Sequencing Market Outlook
- 8.1.□Market Size & Forecast□
- 8.1.1.□By Value
- 8.2.□Market Share & Forecast
- 8.2.1.□By Product (Consumables, Platforms, Services)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.1.1. By Consumables (Sample preparation consumables, Other Consumables)
- 8.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)
- 8.2.1.3. By Services (Sequencing Services, Data management services)
- 8.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
- 8.2.3. By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
- 8.2.4. By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 9. Central France Next-Generation Sequencing Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Product (Consumables, Platforms, Services)
 - 9.2.1.1. By Consumables (Sample preparation consumables, Other Consumables)
 - 9.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)
 - 9.2.1.3. By Services (Sequencing Services, Data management services)
 - 9.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
 - 9.2.3. By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
 - 9.2.4. By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 10. Eastern France Next-Generation Sequencing Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Product (Consumables, Platforms, Services)
 - 10.2.1.1. By Consumables (Sample preparation consumables, Other Consumables)
 - 10.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)
 - 10.2.1.3. By Services (Sequencing Services, Data management services)
 - 10.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
 - 10.2.3. By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
 - 10.2.4. By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 11. Southwestern France Next-Generation Sequencing Market Outlook
 - 11.1. Market Size & Forecast
 - 11.1.1. By Value
 - 11.2. Market Share & Forecast
 - 11.2.1. By Product (Consumables, Platforms, Services)
 - 11.2.1.1. By Consumables (Sample preparation consumables, Other Consumables)
 - 11.2.1.2. By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms)
 - 11.2.1.3. By Services (Sequencing Services, Data management services)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.2.□By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others)
- 11.2.3.□By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others)
- 11.2.4.□By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others)
- 12.□Market Dynamics
 - 12.1.□Drivers
 - 12.2.□Challenges
- 13.□Market Trends & Developments
 - 13.1.□Recent Developments
 - 13.2.□Mergers & Acquisitions
 - 13.3.□Product Launches
- 14.□Policy & Regulatory Landscape
- 15.□Porter's Five Forces Analysis
 - 15.1.□Competition in the Industry
 - 15.2.□Potential of New Entrants
 - 15.3.□Power of Suppliers
 - 15.4.□Power of Customers
 - 15.5.□Threat of Substitute Products
- 16.□France Economic Profile
- 17.□Competitive Landscape
 - 17.1.□Business Overview
 - 17.2.□Product Offerings
 - 17.3.□Recent Developments
 - 17.4.□Financials (As Reported)
 - 17.5.□Key Personnel
 - 17.6.□SWOT Analysis
 - 17.6.1.□Illumina France
 - 17.6.2.□Roche Diagnostics France SAS
 - 17.6.3.□Agilent Technologies, Inc.
 - 17.6.4.□Perkinelmer Inc.
 - 17.6.5.□Amgen Inc.
 - 17.6.6.□Takara Bio Europe
- 18.□Strategic Recommendations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

France Next-Generation Sequencing Market By Product (Consumables, Platforms, Services), By Consumables (Sample preparation consumables, Other Consumables), By Platforms (HiSeq series, MiSeq series, ION Torrent, SOLiD, Pacbio Rs II and Sequel system, Other Sequencing Platforms), By Services (Sequencing Services, Data management services), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing and Others), By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics and Others), By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research and Others), By Region, By Competition Forecast & Opportunities, 2018-2028F

Market Report | 2023-11-07 | 87 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com


ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



\$7500.00

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com





*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

□** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com